Teropavimab
- Generic Name
- Teropavimab
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03719664
- Locations
- 🇺🇸
ABT-3BNC117_201 Investigational Site, New York, New York, United States
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 77
- Registration Number
- NCT03554408
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
3BNC117 and 10-1074 in ART-treated Individuals
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 26
- Registration Number
- NCT03526848
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
🇺🇸Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, United States
3BNC117-LS First-in-Human Phase 1 Study
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 43
- Registration Number
- NCT03254277
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03041012
- Locations
- 🇬🇧
Guy's and St Thomas', London, United Kingdom
🇩🇰Department of Infectious Diseases, Odense, Denmark
🇩🇰Dept. of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
Romidepsin Plus 3BNC117 Phase 2a Study
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 48
- Registration Number
- NCT02850016
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
🇩🇰Aarhus University Hospital, Aarhus, Denmark
🇩🇪University of Cologne, Cologne, Germany
3BNC117 and 10-1074 in HIV-infected Individuals
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 34
- Registration Number
- NCT02825797
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
🇺🇸The Rockefeller University, New York, New York, United States
3BNC117 and 10-1074 in HIV Uninfected Adults
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 24
- Registration Number
- NCT02824536
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
A Study of the Safety and Antiretroviral Activity of 3BNC117
- Conditions
- HIV-1 Infection
- Interventions
- Other: Antiretroviral Treatment Interruption
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 17
- Registration Number
- NCT02588586
- Locations
- 🇺🇸
Weill Cornel Medical Center, New York, New York, United States
🇺🇸The Rockefeller University, New York, New York, United States
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 16
- Registration Number
- NCT02446847
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.